Does presence of left ventricular contractile reserve improve response to cardiac resynchronization therapy? An

Nikolaos Papageorgiou1, Rui Providência2, Pier D Lambiase3

  • 1Echocardiography Laboratory, Barts Heart Centre, St Bartholomew's Hospital, London, UK; Electrophysiology Department, Barts Heart Centre, St Bartholomew's Hospital, London, UK.

Insights

Contractile reserve (CR) predicts better response to cardiac resynchronization therapy (CRT). Identifying CR improves CRT outcomes, especially in patients with narrower QRS complexes, potentially reducing non-response rates.

Area of Science:

  • Cardiology
  • Medical Technology
  • Heart Failure Management

Background:

  • Cardiac resynchronization therapy (CRT) is a treatment for heart failure.
  • A significant portion of patients (up to one-third) do not respond to CRT.
  • Predictors of CRT response, such as contractile reserve (CR), require further investigation.

Purpose of the Study:

  • To determine if the presence of contractile reserve (CR) improves response to cardiac resynchronization therapy (CRT).
  • To investigate whether clinical factors modulate the relationship between CR and CRT response.

Main Methods:

  • A meta-analysis was conducted, searching PubMed, EMBASE, and Cochrane databases.
  • Studies examining CRT response stratified by the presence or absence of CR were included.
  • Response was classified as clinical or echocardiographic, comparing outcomes between patients with and without CR.

Main Results:

  • The analysis included 824 patients from 12 studies.
  • Presence of left ventricular CR significantly reduced both echocardiographic and clinical non-responders to CRT (OR < 0.33, p < 0.00001).
  • Meta-regression indicated CR was associated with lower non-responder rates, more pronounced with narrower QRS complexes.

Conclusions:

  • Identifying contractile reserve (CR) is linked to improved cardiac resynchronization therapy (CRT) response.
  • QRS width may moderate CRT response heterogeneity.
  • Combining CR assessment with QRS width could optimize patient selection and predict CRT outcomes.
Abstract

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
594
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
483
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
403
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
539
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
611
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.6K